Translating Next-Generation Science into Transformative Gene Therapies
Encoded Therapeutics is a clinical-stage biotech company developing precision genetic medicines for severe pediatric central nervous system disorders, with a lead program targeting SCN1A+ Dravet syndrome. The company's novel targeting and regulation platform enables cell-type-specific gene expression, overcoming limitations of first-generation gene therapies. In January 2026, ETX101 received FDA Breakthrough Therapy Designation for the treatment of Dravet syndrome.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2020
Jun 2019
Oct 2014
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
